Physiologically based pharmacokinetic model for topotecan in mice

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 38, Issue 1, 2011, Pages 121-142

  Shah, Dhaval K ^a   Balthasar, Joseph P ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Enterohepatic recycling; PBPK; Pharmacokinetics; Topotecan

Indexed keywords

TOPOTECAN;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BILE LEVEL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG EXPOSURE; DRUG METABOLISM; DRUG PENETRATION; DRUG TISSUE LEVEL; ENTEROHEPATIC CIRCULATION; HEART; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTESTINE; LIVER; LUNG; MALE; MOUSE; MUSCLE; NONHUMAN; NONLINEAR SYSTEM; PARTITION COEFFICIENT; PERITONEAL FLUID; PLASMA CONCENTRATION-TIME CURVE; PREDICTION; PRIORITY JOURNAL; SINGLE DRUG DOSE; SKIN; SPLEEN; TESTIS; TISSUE PERFUSION;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; ENTEROHEPATIC CIRCULATION; INJECTIONS, INTRAVENOUS; MALE; MICE; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; TISSUE DISTRIBUTION; TOPOTECAN;

EID: 79551593085     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10928-010-9181-1     Document Type: Article

References (37)

1. M Markman 1997 Topotecan: an important new drug in the management of ovarian cancer Semin Oncol 24 1 Suppl 5 S1 S5
2. A Anand SY Chan 2004 The use of topotecan for relapsed ovarian cancer in accordance with the National Institute for Clinical Excellence guidance 2001: the Nottingham experience Clin Oncol (R Coll Radiol) 16 8 543 548 1:STN:280:DC%2BD2M%2FgsFeqtw%3D%3D
3. VM Herben WW ten Bokkel Huinink JH Beijnen 1996 Clinical pharmacokinetics of topotecan Clin Pharmacokinet 31 2 85 102 1:CAS:528:DyaK28Xltlant7c%3D 10.2165/00003088-199631020-00001 8853931
4. CH Takimoto SG Arbuck 1997 Clinical status and optimal use of topotecan Oncology (Williston Park) 11 11 1635 1646 1:STN:280:DyaK1c%2Fls1aisg%3D%3D
5. RN Brogden LR Wiseman 1998 Topotecan. A review of its potential in advanced ovarian cancer Drugs 56 4 709 723 1:CAS:528:DyaK1cXnsVWis7c%3D 10.2165/00003495-199856040-00017 9806112
6. C Kollmannsberger K Mross A Jakob L Kanz C Bokemeyer 1999 Topotecan-a novel topoisomerase I inhibitor: pharmacology and clinical experience Oncology 56 1 1 12 1:CAS:528:DyaK1MXhtV2lsrY%3D 10.1159/000011923 9885371
7. WC Zamboni PJ Houghton RK Johnson JL Hulstein WR Crom PJ Cheshire SK Hanna LB Richmond X Luo CF Stewart 1998 Probenecid alters topotecan systemic and renal disposition by inhibiting renal tubular secretion J Pharmacol Exp Ther 284 1 89 94 1:CAS:528:DyaK1cXltlCmug%3D%3D 9435165
8. S Guichard A Montazeri E Chatelut I Hennebelle R Bugat P Canal 2001 Schedule-dependent activity of topotecan in ovcar-3 ovarian carcinoma xenograft: pharmacokinetic and pharmacodynamic evaluation Clin Cancer Res 7 10 3222 3228 1:CAS:528:DC%2BD3MXnvF2rs78%3D 11595718
9. LJ van Warmerdam WW ten Bokkel Huinink S Rodenhuis I Koier BE Davies H Rosing RA Maes JH Beijnen 1995 Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion J Clin Oncol 13 7 1768 1776 7602366
10. J Chen Q Lu JP Balthasar 2007 Mathematical modeling of topotecan pharmacokinetics and toxicodynamics in mice J Pharmacokinet Pharmacodyn 34 6 829 847 10.1007/s10928-007-9072-2 17885736
11. VM Herben E Schoemaker H Rosing DM van Zomeren WW ten Bokkel Huinink R Dubbelman S Hearn JH Schellens JH Beijnen 2002 Urinary and fecal excretion of topotecan in patients with malignant solid tumours Cancer Chemother Pharmacol 50 1 59 64 1:CAS:528:DC%2BD38XkvVagu7Y%3D 10.1007/s00280-002-0454-2 12111113
12. H Rosing VM Herben DM van Gortel-van Zomeren E Hop JJ Kettenes-van den Bosch WW ten Bokkel Huinink JH Beijnen 1997 Isolation and structural confirmation of n-desmethyl topotecan, a metabolite of topotecan Cancer Chemother Pharmacol 39 6 498 504 1:CAS:528:DyaK2sXis1ajtrg%3D 10.1007/s002800050605 9118461
13. H Rosing DM van Zomeren E Doyle A Bult JH Beijnen 1998 O-glucuronidation, a newly identified metabolic pathway for topotecan and n-desmethyl topotecan Anticancer Drugs 9 7 587 592 1:CAS:528:DyaK1cXntVWrtb4%3D 10.1097/00001813- 199808000-00002 9773801
14. M Leggas M Adachi GL Scheffer D Sun P Wielinga G Du KE Mercer Y Zhuang JC Panetta B Johnston RJ Scheper CF Stewart JD Schuetz 2004 Mrp4 confers resistance to topotecan and protects the brain from chemotherapy Mol Cell Biol 24 17 7612 7621 1:CAS:528:DC%2BD2cXntVKhurs%3D 10.1128/MCB.24.17.7612-7621.2004 15314169
15. NA de Vries J Zhao E Kroon T Buckle JH Beijnen O van Tellingen 2007 P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan Clin Cancer Res 13 21 6440 6449 10.1158/1078-0432.CCR-07-1335 17975156
16. JW Jonker JW Smit RF Brinkhuis M Maliepaard JH Beijnen JH Schellens AH Schinkel 2000 Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan J Natl Cancer Inst 92 20 1651 1656 1:CAS:528:DC%2BD3cXnvV2mtbw%3D 10.1093/jnci/92.20.1651 11036110
17. CB Hendricks EK Rowinsky LB Grochow RC Donehower SH Kaufmann 1992 Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue Cancer Res 52 8 2268 2278 1:CAS:528:DyaK38Xkt1Sjtrw%3D 1348448
18. F Leger WJ Loos J Fourcade R Bugat M Goffinet RH Mathijssen J Verweij A Sparreboom E Chatelut 2004 Factors affecting pharmacokinetic variability of oral topotecan: a population analysis Br J Cancer 90 2 343 347 1:CAS:528: DC%2BD2cXksl2ntw%3D%3D 10.1038/sj.bjc.6601469 14735174
19. J Chen JP Balthasar 2005 High-performance liquid chromatographic assay for the determination of total and free topotecan in the presence and absence of anti-topotecan antibodies in mouse plasma J Chromatogr B 816 1-2 183 192 1:CAS:528:DC%2BD2MXmvFaitg%3D%3D 10.1016/j.jchromb.2004.11.035
20. JR Nedelman E Gibiansky DT Lau 1995 Applying bailer's method for AUC confidence intervals to sparse sampling Pharm Res 12 1 124 128 1:CAS:528:DyaK2MXjt12it7k%3D 10.1023/A:1016255124336 7724473
21. DJ Holder 2001 Comments on nedelman and jia's extension of satterthwaite's approximation applied to pharmacokinetics J Biopharm Stat 11 1-2 75 79 1:STN:280:DC%2BD38%2FitlSqtQ%3D%3D 10.1081/BIP-100104199 11459444
22. M De Cesare F Zunino S Pace C Pisano G Pratesi 2000 Efficacy and toxicity profile of oral topotecan in a panel of human tumour xenografts Eur J Cancer 36 12 1558 1564 10.1016/S0959-8049(00)00141-6 10930804
23. Fujita H, Okamoto M, Takao A, Abe H, Ishii R, Arase H (1995) Pharmacokinetics of SK & F 104864 in experimental animals. II. Tissue distribution. Gan To Kagaku Ryoho 22(12):1789-1792
24. J Balthasar HL Fung 1994 Utilization of antidrug antibody fragments for the optimization of intraperitoneal drug therapy: studies using digoxin as a model drug J Pharmacol Exp Ther 268 2 734 739 1:CAS:528:DyaK2cXitVSgs78%3D 8113985
25. JP Balthasar HL Fung 1996 Inverse targeting of peritoneal tumors: selective alteration of the disposition of methotrexate through the use of anti-methotrexate antibodies and antibody fragments J Pharm Sci 85 10 1035 1043 1:CAS:528:DyaK28XlsVynu7w%3D 10.1021/js960135w 8897267
26. PJ O'Dwyer FP LaCreta NB Haas T Halbherr H Frucht E Goosenberg KS Yao 1994 Clinical, pharmacokinetic and biological studies of topotecan Cancer Chemother Pharmacol 34 Suppl S46 S52 10.1007/BF00684863 8070027
27. LB Grochow EK Rowinsky R Johnson S Ludeman SH Kaufmann FL McCabe BR Smith L Hurowitz A DeLisa RC Donehower, et al. 1992 Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer Drug Metab Dispos 20 5 706 713 1:CAS:528:DyaK38XmtVCnu7c%3D 1358575
28. Strel'tsov SA, Mikheikin AL, Grokhovskii SL, Oleinikov VA, Kudelina IA, Zhuze AL (2002) Interaction of topotecan, DNA topoisomerase I inhibitor, with double-stranded polydeoxyribonucleotides. 4. Topotecan binds preferably to the GC base pairs of DNA. Mol Biol (Mosk) 36(5):912-930
29. Y Zhuang CH Fraga KE Hubbard N Hagedorn JC Panetta CM Waters CF Stewart 2006 Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor Cancer Res 66 23 11305 11313 1:CAS:528:DC%2BD28Xht1KnsLzP 10.1158/0008-5472.CAN-06-0929 17145877
30. KB Bischoff RL Dedrick DS Zaharko JA Longstreth 1971 Methotrexate pharmacokinetics J Pharm Sci 60 8 1128 1133 1:CAS:528:DyaE3MXkvFKqurk%3D 10.1002/jps.2600600803 5127083
31. T Yamagata H Kusuhara M Morishita K Takayama H Benameur Y Sugiyama 2007 Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients Drug Metab Dispos 35 7 1142 1148 1:CAS:528:DC%2BD2sXns1yhs78%3D 10.1124/dmd.106.014217 17446265
32. F Fenneteau J Turgeon L Couture V Michaud J Li F Nekka 2009 Assessing drug distribution in tissues expressing P-glycoprotein through physiologically based pharmacokinetic modeling: model structure and parameters determination Theor Biol Med Model 6 2 1 13
33. LT Baxter H Zhu DG Mackensen WF Butler RK Jain 1995 Biodistribution of monoclonal antibodies: scale-up from mouse to human using a physiologically based pharmacokinetic model Cancer Res 55 20 4611 4622 1:CAS:528: DyaK2MXoslWmsLo%3D 7553638
34. RP Brown MD Delp SL Lindstedt LR Rhomberg RP Beliles 1997 Physiological parameter values for physiologically based pharmacokinetic models Toxicol Ind Health 13 4 407 484 1:CAS:528:DyaK2sXltl2itrk%3D 9249929
35. B Davies T Morris 1993 Physiological parameters in laboratory animals and humans Pharm Res 10 7 1093 1095 1:STN:280:DyaK3szptFaqsg%3D%3D 10.1023/A:1018943613122 8378254
36. TR Fennell CD Brown 2001 A physiologically based pharmacokinetic model for ethylene oxide in mouse, rat, and human Toxicol Appl Pharmacol 173 3 161 175 1:CAS:528:DC%2BD3MXkvVOku74%3D 10.1006/taap.2001.9184 11437638
37. JM Gearhart GW Jepson HJ Clewell ME Andersen RB Conolly 1994 Physiologically based pharmacokinetic model for the inhibition of acetylcholinesterase by organophosphate esters Environ Health Perspect 102 Suppl 11 51 60 1:CAS:528:DyaK2MXltlGitbs%3D 7737042